216 related articles for article (PubMed ID: 35608811)
1.
Bashari WA; van der Meulen M; MacFarlane J; Gillett D; Senanayake R; Serban L; Powlson AS; Brooke AM; Scoffings DJ; Jones J; O'Donovan DG; Tysome J; Santarius T; Donnelly N; Boros I; Aigbirhio F; Jefferies S; Cheow HK; Mendichovszky IA; Kolias AG; Mannion R; Koulouri O; Gurnell M
Pituitary; 2022 Aug; 25(4):573-586. PubMed ID: 35608811
[TBL] [Abstract][Full Text] [Related]
2. Implementation of functional imaging using
Bakker LEH; Verstegen MJT; Ghariq E; Verbist BM; Schutte PJ; Bashari WA; Kruit MC; Pereira AM; Gurnell M; Biermasz NR; van Furth WR; Bouda LMPA
Pituitary; 2022 Aug; 25(4):587-601. PubMed ID: 35616762
[TBL] [Abstract][Full Text] [Related]
3. Recurrence of hyperprolactinaemia following discontinuation of dopamine agonist therapy in patients with prolactinoma occurs commonly especially in macroprolactinoma.
Barber TM; Kenkre J; Garnett C; Scott RV; Byrne JV; Wass JA
Clin Endocrinol (Oxf); 2011 Dec; 75(6):819-24. PubMed ID: 21645021
[TBL] [Abstract][Full Text] [Related]
4. Endoscopic Transnasal Approach for Microprolactinomas with Experience of 105 Cases in a Single Center: Paradigmal Shift for Conventional Medical Therapy.
Uzuner A; Yilmaz E; Caklili M; Selek A; Aydemir F; Cabuk B; Anik I; Ceylan S
World Neurosurg; 2023 Feb; 170():e858-e867. PubMed ID: 36481446
[TBL] [Abstract][Full Text] [Related]
5. Prolactinoma surgery.
Jan M; Dufour H; Brue T; Jaquet P
Ann Endocrinol (Paris); 2007 Jun; 68(2-3):118-9. PubMed ID: 17512893
[TBL] [Abstract][Full Text] [Related]
6. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas.
Di Sarno A; Landi ML; Marzullo P; Di Somma C; Pivonello R; Cerbone G; Lombardi G; Colao A
Clin Endocrinol (Oxf); 2000 Jul; 53(1):53-60. PubMed ID: 10931080
[TBL] [Abstract][Full Text] [Related]
7. Endoscopic Transsphenoidal Surgery of Microprolactinomas: A Reappraisal of Cure Rate Based on Radiological Criteria.
Micko A; Vila G; Höftberger R; Knosp E; Wolfsberger S
Neurosurgery; 2019 Oct; 85(4):508-515. PubMed ID: 30169711
[TBL] [Abstract][Full Text] [Related]
8. Clinical application of combination [
Wang Z; Feng Z; Zhu D; Wang X; Chen J; Zhu Y; Wang H
BMC Endocr Disord; 2024 Feb; 24(1):19. PubMed ID: 38311763
[TBL] [Abstract][Full Text] [Related]
9. 18F-FDOPA Uptake Reflects the Efficacy of Dopamine Agonists Treatment in Pituitary Prolactinoma.
Heimburger C; Bund C; Addeo P; Goichot B; Imperiale A
Clin Nucl Med; 2018 Sep; 43(9):e324-e325. PubMed ID: 30052596
[TBL] [Abstract][Full Text] [Related]
10. SURGICAL OUTCOMES OF PROLACTINOMAS IN RECENT ERA: RESULTS OF A HETEROGENOUS GROUP.
Donegan D; Atkinson JL; Jentoft M; Natt N; Nippoldt TB; Erickson B; Meyer F; Erickson D
Endocr Pract; 2017 Jan; 23(1):37-45. PubMed ID: 27682355
[TBL] [Abstract][Full Text] [Related]
11. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia.
Colao A; Di Sarno A; Cappabianca P; Di Somma C; Pivonello R; Lombardi G
N Engl J Med; 2003 Nov; 349(21):2023-33. PubMed ID: 14627787
[TBL] [Abstract][Full Text] [Related]
12. Successful treatment of residual pituitary adenoma in persistent acromegaly following localisation by 11C-methionine PET co-registered with MRI.
Koulouri O; Kandasamy N; Hoole AC; Gillett D; Heard S; Powlson AS; O'Donovan DG; Annamalai AK; Simpson HL; Akker SA; Aylwin SJ; Brooke A; Buch H; Levy MJ; Martin N; Morris D; Parkinson C; Tysome JR; Santarius T; Donnelly N; Buscombe J; Boros I; Smith R; Aigbirhio F; Antoun NM; Burnet NG; Cheow H; Mannion RJ; Pickard JD; Gurnell M
Eur J Endocrinol; 2016 Nov; 175(5):485-498. PubMed ID: 27562400
[TBL] [Abstract][Full Text] [Related]
13. In vivo imaging of pituitary tumours using a radiolabelled dopamine D2 receptor radioligand.
de Herder WW; Reijs AE; Kwekkeboom DJ; Hofland LJ; Nobels FR; Oei HY; Krenning EP; Lamberts SW
Clin Endocrinol (Oxf); 1996 Dec; 45(6):755-67. PubMed ID: 9039343
[TBL] [Abstract][Full Text] [Related]
14. [Hyperprolactinemia: unusual association between peripheral hypothyroidism and microprolactinoma].
Chafik A; El Mghari G; El Ansari N
Pan Afr Med J; 2016; 24():41. PubMed ID: 27642382
[TBL] [Abstract][Full Text] [Related]
15. Surgical outcomes in hyporesponsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists.
Hamilton DK; Vance ML; Boulos PT; Laws ER
Pituitary; 2005; 8(1):53-60. PubMed ID: 16411069
[TBL] [Abstract][Full Text] [Related]
16. Clinical, Hormonal, and Neuroradiological Characteristics and Therapeutic Outcomes of Prolactinomas in Children and Adolescents at a Single Center.
Yang A; Cho SY; Park H; Kim MS; Kong DS; Shin HJ; Jin DK
Front Endocrinol (Lausanne); 2020; 11():527. PubMed ID: 32849307
[No Abstract] [Full Text] [Related]
17. The assessment of cabergoline efficacy and tolerability in patients with pituitary prolactinoma type.
Bolko P; Jaskuła M; Waśko R; Wołuń M; Sowiński J
Pol Arch Med Wewn; 2003 May; 109(5):489-95. PubMed ID: 14768178
[TBL] [Abstract][Full Text] [Related]
18. DRD2 expression based on
Tang H; Cheng Y; Lou X; Yao H; Xie J; Gu W; Huang X; Liu Y; Lin S; Dai Y; Xue L; Lin X; Wu ZB
Endocrine; 2023 May; 80(2):419-424. PubMed ID: 36689171
[TBL] [Abstract][Full Text] [Related]
19. Effect of dopamine agonists on prolactinomas and normal pituitary assessed by dynamic contrast enhanced magnetic resonance imaging (DCE-MRI).
Manuchehri AM; Sathyapalan T; Lowry M; Turnbull LW; Rowland-Hill C; Atkin SL
Pituitary; 2007; 10(3):261-6. PubMed ID: 17557207
[TBL] [Abstract][Full Text] [Related]
20. Utility of 11C-Methionine and 18F-FDG PET/CT in Patients With Functioning Pituitary Adenomas.
Feng Z; He D; Mao Z; Wang Z; Zhu Y; Zhang X; Wang H
Clin Nucl Med; 2016 Mar; 41(3):e130-4. PubMed ID: 26646998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
